2026-04-29T22:57:41Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/262402025-12-18T12:53:10Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16927col_20.500.12105_16977col_20.500.12105_16978col_20.500.12105_16982col_20.500.12105_16984

00925njm 22002777a 4500 dc de la Haba-Rodríguez, J R author Mínguez, P author Rojo, F author Martín, M author Alba, E author Servitja, S author Prat, A author Pérez-Fidalgo, Jose Alejandro author Gavilá, J author Morales, C author Rodriguez-Lescure, A author Herrero, C author Peña-Enriquez, R author Herranz, J author Hernando, C author Hernández-Blanquisett, A author Guil-Luna, S author Martinez, M T author Blanch, S author Caballero, R author Martín, N author Pollan-Santamaria, Marina author Guerrero-Zotano, Ángel author Bermejo, B author 2024-11-08 Gestational breast cancer (GBC), defined as breast cancer (BC) diagnosed during pregnancy or the first-year post-partum, accounts for 6-15% of BC cases in women aged 20-44 years. GBC has worse prognosis than non-GBC, but reasons behind are not clear. The GEICAM/2012-03 Study (Molecular Characterization of Gestational Breast Cancer) is a multicenter prospective/retrospective observational registry of patients diagnosed with GBC. From November 2014 to June 2015 seventy patients diagnosed with GBC were included in the study, 30 diagnosed during pregnancy and 40 after delivery. Our current study was aimed to explore differences in epidemiological, clinico-pathological and gene expression features of GBC tumors, from the GEICAM/2012-03 Study, compared to non-GBC tumors from patients of similar age (< 43 years) from six different GEICAM studies, used as non- GBC control population. As per the main objective, the study found multiple differences showing GBC tumors as a different biological entity. GBC showed a more aggressive biology, with higher Ki67 levels, higher incidence of breast and/or ovarian cancer family history, and germline deleterious BRCA1/2 mutations, and are enriched in basal-like intrinsic subtype. GBC patients showed a lower number of tumor infiltrating lymphocytes, while specific genetic signatures highlight differences in GBC´s distinctive transcriptome. Our study shows that GBC is potentially a clinically and molecularly different entity, with specific epidemiological, clinical, and histological features, as well as a distinctive altered immune state and genetic signature. Nevertheless, further studies are needed to better understand the biology of GBC and to identify new targets against which develop new, more effective, targeted therapies. de la Haba-Rodríguez JR, Mínguez P, Rojo F, Martín M, Alba E, Servitja S, Prat A, Pérez-Fidalgo JA, Gavilá J, Morales C, Rodriguez-Lescure A, Herrero C, Peña-Enriquez R, Herranz J, Hernando C, Hernández-Blanquisett A, Guil-Luna S, Martinez MT, Blanch S, Caballero R, Martín N, Pollán M, Guerrero-Zotano A, Bermejo B. Gestational breast cancer: distinctive molecular and clinico-epidemiological features. J Mammary Gland Biol Neoplasia. 2024 Nov 8;29(1):18. 10.1007/s10911-024-09571-3 1573-7039 1083-3021 Journal of mammary gland biology and neoplasia 39514034 https://hdl.handle.net/20.500.12105/26240 Breast cancer Gene expression Gestation Gestational breast cancer PAM50 intrinsic subtypes Tumor infiltrating lymphocytes (TILs) Gestational breast cancer: distinctive molecular and clinico-epidemiological features